Elderly patients with acute myeloid leukemia (AML) have limited treatment options
concerned about their overall fitness and potential treatment related mortality. Although a …

Despite widespread use of decitabine to treat acute myeloid leukaemia (AML), data on its
effectiveness and safety in the real‐world setting are scanty. Thus, to analyze the …

Decitabine (Dacogen®) is a deoxynucleoside analogue of cytidine that selectively inhibits
DNA methyltransferases. Decitabine administered at a dose of 20 mg/m 2 by a 1-h …

Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have
been widely used in the management of elderly patients with acute myeloid leukemia (AML) …

Purpose Older patients with acute myeloid leukemia (AML) have limited treatment options
because of the lack of effectiveness and the toxicity of available therapies. We investigated …

Purpose This multicenter, randomized, open-label, phase III trial compared the efficacy and
safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute …

The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor
prognosis despite induction therapy. Decitabine, a DNA-hypomethylating agent that induces …

Abstract Background The hypomethylating agent Decitabine (DAC) is a valuable treatment
option in acute myeloid leukemia (AML), particularly in elderly patients (pts) not suitable for …

Background In a multicenter, randomized, open-label phase III study, patients≥ 65 years
with newly diagnosed AML received decitabine 20 mg/m 2 once daily for 5 days every 4 …

Decitabine (Dacogen™) was recently approved for the treatment of patients with
myelodysplastic syndromes (MDS). Response in MDS is associated with reversal of the …